摘要
目的检测EZH2和RUNX3蛋白在肾细胞癌中的表达,探讨它们与肾细胞癌临床病理特征间的关系,并分析它们的表达相关性。方法利用免疫组织化学法分别检测肾细胞癌标本及对应的癌旁正常肾组织(各56例)中EZH2和RUNX3的表达情况,并利用统计学软件进行统计分析。结果 EZH2和RUNX3蛋白在肾癌组织中的阳性表达率分别为67.9%和37.5%,在癌旁正常肾组织的阳性表达率分别为28.6%和67.3%;EZH2和RUNX3在肾癌组织和癌旁正常组织中的表达差异均有统计学意义(P<0.05),肾细胞癌中EZH2的高表达和RUNX3的低表达均与临床分期相关(P<0.05),与病理分化程度、性别、年龄等的关系无统计学差异(P>0.05)。Spearman相关分析显示二者在肾癌中的表达没有明显的负相关关系。结论 EZH2和RUNX3可能共同参与了肾癌的发生发展过程,可成为肾癌的早期诊断及判断预后的指标。
Objective To investigate the expression levels of enhancer of zeste homolog 2 （EZH2） and human runt-related transcription factor 3 （RUNX3） in renal cell carcinoma （RCC）, and analyze their clinical significance and expression correlation. Methods Expressions of EZH2 and RUNX3 proteins were analyzed by immunohistochemistry in 56 RCC tissues and corresponding adjacent normal renal tissues, respectively. Statistic analysis was conducted using SPSSI？. 0 software. Results Immunohistochemistry revealed that the positive rates of EZH2 and RUNX3 expressions were 67.9% and 37.5% in RCC tissues, respectively, and they were 28.6% and 67.3% in adjacent normal renal tissues. The expressions of EZHZ and RUNX3 between RCC and normal renal tissues were significantly different （P〈0.05）. High expression of EZH2 and low expression of RUNX3 in RCC were associated with the clinical stage （P〈0.0.5）, but not associated with pathological differ- entiation, age or gender （ P 〉 0.05 ）. No statistically significant negative correlation was observed in the expressions of EZH2 and RUNX3 in RCC （P 〉 0.05 ）. Conclusion Both EZH2 and RUNX3 may play important roles in the development and progression of RCC, and the detection on EZH2 and RUNX3 expressions will be helpful for early diagnosis and prognosis prediction of RCC.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2013年第1期82-84,88,共4页
Chinese Journal of Cellular and Molecular Immunology
基金
国家自然科学基金面上项目(81171924
81172146)
国家重点基础研究发展计划(973)资助项目(2009CB521703)
